Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Minneapolis, MN, Jan. 11, 2017 -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace, announced that the company’s PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, was featured in the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology. The article entitled Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals highlights the potential benefits of using BioSig’s PURE EP System compared to a standard recording system. The study was completed by the team led by Dr. Samuel Asirvatham at Mayo Clinic in Rochester, Minnesota.
“We are pleased to have such a prestigious journal recognize the potential advantages of the PURE EP System,” said Jay Millerhagen, BioSig’s Vice President of Clinical Research.
The study focused on signals from the Purkinje network in the heart’s ventricles or lower chambers of the heart. Many ventricular arrhythmias are initiated in the Purkinje fiber conduction system. Ventricular arrhythmias are a major source of sudden death, which accounts for approximately half of cardiac mortality. This study proved that by using BioSig’s PURE EP System during catheter ablation, doctors may be better able to treat these types of complex arrhythmias.
About JACC Journals
The Journal of the American College of Cardiology program is the best read cardiovascular journal program worldwide, with an international reputation for excellence. JACC is consistently rated the number one benefit of membership in the American College of Cardiology, and maintains the highest Impact Factor in the area of cardiovascular medicine. The JACC journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, review articles, and editorials interpreting and commenting on the research presented.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) (biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; and has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, an Advanced Research Program at Mayo Clinic began in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
Investor Relations: Brian McLaughlin BioSig Technologies, Inc. [email protected] 917-370-9817 Robert Haag IRTH Communications [email protected] 866-976-4784
